IndonesiaSingaporeMalaysiaVietnamThailandPhilippinesMyanmar
IndiaGreater ChinaRest of AsiaWorld
E-Commerce & Internet EconomyTechnologyReal Estate and InfrastructureFinancial ServicesSocial InfrastructureDeals Barometer

China's Yisheng Biopharma nets $130m in Series B round co-led by OrbiMed

China's Yisheng Biopharma nets $130m in Series B round co-led by OrbiMed

Liya Su

24 February, 2021

China’s Yisheng Biopharma Ltd has closed its $130-million Series B round co-led by returning investor OrbiMed and deep tech-focused investor Oceanpine Capital.

Oceanpine CapitalOrbiMedYisheng Biopharma

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter

Related Stories

Private Equity

ADB invests $75m in OrbiMed's fourth Asia-focused healthcare PE fund

This marks the third investment by ADB in funds managed by OrbiMed.

Deals

GL Ventures, Temasek co-lead $230m round in China's Clover Biopharmaceuticals

The corpus raised will help Clover build a pipeline of protein-based vaccines, among others.
Nikkei Logo
DealStreetAsia Logo
About Us
Team
Advertise
Contact
Careers
Blog
Privacy Policy
Terms & Conditions
© Copyright DEALSTREETASIA 2014-2023 All rights reserved.